Syntekabio and Enamine partner for AI-based drug development

Syntekabio has entered a partnership with Enamine for supply, synthesis of compounds and synthetic drug development.

Sep 4, 2024 - 04:00

Syntekabio and Enamine partner for AI-based drug development

Syntekabio has entered a partnership with Enamine for supply, synthesis of compounds and synthetic drug development.

Read the original article

Tags:

Previous Article

Why the Importer of Record (IoR) is vital in the clinical supply chain

ESC 2024: Beta blocker treatment paradigm shifts for myocardial infarction

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Rohto Pharmaceutical gets grant for ophthalmic composit...

Mar 30, 2024

STAT+: 4 ways the health care system should shift its thinking on AI, according to experts

STAT+: 4 ways the health care system should shift its t...

May 5, 2023

STAT+: In an unusual arrangement, UnitedHealth’s board chair also owns a personal investment firm

STAT+: In an unusual arrangement, UnitedHealth’s board ...

Oct 18, 2023